Biotech IV Monitor

HRMY — Harmony Biosciences Holdings Inc.

$2.0B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Harmony Biosciences Holdings Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.

Next readoutApril 2027in ~5 months
Upcoming readouts44 Phase 3
Market cap$2.0B
Cash & investments$1.05Bas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-04

Upcoming readouts

Phase 3 Pitolisant tablet
Prader-Willi Syndrome · NCT06366464
April 2027
Recruiting
Phase 3 HBS-301 tablet
Idiopathic Hypersomnia · NCT07500090
October 2027
Recruiting
Phase 3 HBS-301
EDS; Cataplexy · NCT07675135
October 2027
Recruiting
Phase 3 Pitolisant
Prader-Willi Syndrome · NCT07219485
August 2030
Enrolling

Cash position

Harmony Biosciences Holdings Inc. reported $1.05B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $48M for that quarter.

Recent SEC filings

8-K Reg FD Disclosure — often a data announcement2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow HRMY, you can start the conversation.
Track HRMY in real time
See live implied volatility for HRMY and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on HRMY
Contact — questions or corrections about HRMY: dukeupt@gmail.com